Overview

* Sensei Biotherapeutics ( SNSE ) reports Q3 net loss of $4.6 mln, down from $7.3 mln last year

* Company reduces workforce by 65% to preserve cash

Outlook

* Sensei Biotherapeutics ( SNSE ) exploring strategic alternatives, including asset sales and potential merger

* Company implements workforce reduction to preserve cash amid strategic review

* Sensei retains small team for compliance and strategic exploration

Result Drivers

* WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review

* R&D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$3.62

Q3 Net -$4.57

Income mln

Q3 -$4.85

Income mln

From

Operatio

ns

Q3 $4.85

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)